Cargando…
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE®) antibody construct for treatment of leukemia. Transient elevation of cytokines (interleukin (IL)-6, IL-10, interferon-gamma (IFN-γ)) has been observed within the first 48 hours of continuous intravenous blinatumomab infusion. In human hepa...
Autores principales: | Xu, Y, Hijazi, Y, Wolf, A, Wu, B, Sun, Y-N, Zhu, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592530/ https://www.ncbi.nlm.nih.gov/pubmed/26451330 http://dx.doi.org/10.1002/psp4.12003 |
Ejemplares similares
-
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
por: Hijazi, Youssef, et al.
Publicado: (2018) -
Cytochrome P450-Mediated Phytoremediation using Transgenic Plants: A Need for Engineered Cytochrome P450 Enzymes
por: Kumar, Santosh, et al.
Publicado: (2012) -
Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
por: Cho, Hyun-Jong, et al.
Publicado: (2015) -
Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain
por: Burris-Hiday, Sarah D., et al.
Publicado: (2023) -
Structure and function of the cytochrome P450 peroxygenase enzymes
por: Munro, Andrew W., et al.
Publicado: (2018)